Appropriate dose of regorafenib based on body weight of colorectal cancer patients: a retrospective cohort study.

dc.contributor.author

Nakashima, Masayuki

dc.contributor.author

Li, Kan

dc.contributor.author

Chen, Qichen

dc.contributor.author

de Silva, Sajith

dc.contributor.author

Li, Hal

dc.contributor.author

Kawakami, Koji

dc.contributor.author

Wei, Qingyi

dc.contributor.author

Luo, Sheng

dc.contributor.author

Zhao, Hong

dc.date.accessioned

2024-01-02T03:32:04Z

dc.date.available

2024-01-02T03:32:04Z

dc.date.issued

2023-12-21

dc.description.abstract

PURPOSE: Previous randomized studies have shown a survival benefit of using regorafenib but a high rate of adverse events in unresectable colorectal cancer patients. To reduce these adverse events and improve the tolerability, we examined the appropriate dose of regorafenib based on body weight. METHODS: We used a nationwide claims database in Japan and examined the efficacy and safety of regorafenib for patients with metastatic colorectal cancer between groups divided by body weight (60 kg) and median average dose (120 mg) between 2013 and 2018. We also assessed overall survival (OS) and adverse events between these groups. RESULTS: We identified 2530 Japanese patients (heavy weight/high dose: 513, light weight/low dose: 921, heavy weight/low dose: 452, and light weight/high dose: 644). There was no significant difference in the adverse events and OS after inverse probability treatment weighting (IPTW) adjustment between heavy weight/high dose group and light weight/low dose group (hazard ratio, HR=0.97). Among the light-weight patients, higher average dose was associated with shorter OS (IPTW adjusted HR=1.21, 95% CI 1.05 - 1.39, Table 3) while among the heavy-weight patients, there was no significant difference in OS between high and low dose groups (IPTW adjusted HR=1.14, 95% CI 0.95 - 1.37). CONCLUSION: The findings suggest that a low dose of regorafenib for light-weight patients may be as safe and effective as high doses for heavy-weight patients. Further studies should be conducted to identify an appropriate dose based on each patient's physique and condition.

dc.identifier

10.1186/s12885-023-11720-6

dc.identifier.issn

1471-2407

dc.identifier.uri

https://hdl.handle.net/10161/29605

dc.language

eng

dc.publisher

Springer Science and Business Media LLC

dc.relation.ispartof

BMC Cancer

dc.relation.isversionof

10.1186/s12885-023-11720-6

dc.rights.uri

https://creativecommons.org/licenses/by-nc/4.0

dc.subject

Cohort study

dc.subject

Colorectal cancer

dc.subject

Drug therapy

dc.subject

Reduced dose

dc.subject

Regorafenib

dc.subject

Humans

dc.subject

Retrospective Studies

dc.subject

Pyridines

dc.subject

Phenylurea Compounds

dc.subject

Colorectal Neoplasms

dc.subject

Body Weight

dc.title

Appropriate dose of regorafenib based on body weight of colorectal cancer patients: a retrospective cohort study.

dc.type

Journal article

duke.contributor.orcid

Wei, Qingyi|0000-0002-3845-9445|0000-0003-4115-4439

duke.contributor.orcid

Luo, Sheng|0000-0003-4214-5809

pubs.begin-page

1268

pubs.issue

1

pubs.organisational-group

Duke

pubs.organisational-group

School of Medicine

pubs.organisational-group

Basic Science Departments

pubs.organisational-group

Clinical Science Departments

pubs.organisational-group

Institutes and Centers

pubs.organisational-group

Biostatistics & Bioinformatics

pubs.organisational-group

Medicine

pubs.organisational-group

Medicine, Medical Oncology

pubs.organisational-group

Duke Cancer Institute

pubs.organisational-group

Duke Clinical Research Institute

pubs.organisational-group

Institutes and Provost's Academic Units

pubs.organisational-group

University Institutes and Centers

pubs.organisational-group

Duke Global Health Institute

pubs.organisational-group

Population Health Sciences

pubs.organisational-group

Biostatistics & Bioinformatics, Division of Biostatistics

pubs.publication-status

Published online

pubs.volume

23

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
2023Nakashima_et_al2023BMC_Cancer.pdf
Size:
1.23 MB
Format:
Adobe Portable Document Format
Description:
Published version